Seeking AlphaCodex · 实盘不做把握 8/10
北京时间·🕒 发布 01:11:52时区推断·⟳ 抓取 01:14:08·⚡ 决策 07-29 01:15:09 +1m01s·90.7 天前
Teva 二季度财报前瞻显示市场预期疲弱但尚无新增公司事实
这条信号只是 Seeking Alpha 对 7月29日盘前财报的预期汇总，EPS、收入预期和下修次数均属于财报前已知的市场预期，不是 Teva 新披露的业绩或指引。
📄 原文Seeking Alpha↗ 原文
Teva's Q2 earnings on deck: What to expect
Analysts have projected a grim second-quarter print for Teva Pharmaceutical (TEVA), which is expected to report its res…
不做 Teva Pharmaceutical（TEVA.US）
财报前瞻只汇总已知一致预期和关注点，未披露实际业绩、正式指引修正或公司级新增事实；等 7月29日盘前正式财报后再由新信号研判。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-28 · 扩散 medium · price-in 风险 high ↗
关键理由
- 这条信号只是 Seeking Alpha 对 7月29日盘前财报的预期汇总，EPS、收入预期和下修次数均属于财报前已知的市场预期，不是 Teva 新披露的业绩或指引。
- 正文没有新增订单、获批、诉讼结果、正式指引修正或财报 surprise，无法形成同向可交易催化。
- A股/港股无明确供应链或竞争替代映射，且药品 ecopipam 仍处 FDA NDA 阶段，未构成当日可交易的商业化落地事件。
主要风险
- 真正的可交易事件要等 2026-07-29 盘前 Teva 正式财报、管理层指引或 ecopipam/诉讼新增事实披露后重新研判。
原文全文
展开原文 · 1,997 字
Analysts have projected a grim second-quarter print for Teva Pharmaceutical (TEVA), which is expected to report its results on July 29, before the market opens.
Wall Street has projected an 83% decline in its EPS to $0.11, while revenue is expected to dip slightly by about 4% to $4.03B.
Over the last 3 months, EPS as well as revenue estimates have seen 0 upward revisions and 7 downward moves, representing a bearish setup ahead of the earnings.
Last quarter, the Israeli drugmaker beat analyst estimates but cut its full-year adjusted earnings outlook by $0.66 to the range of $1.91 - $2.11. The reduction was due to its $900M acquisition of Chicago, Illinois-based biotech firm Emalex Biosciences.
While the deal’s impact has been priced in in its full-year forecast, its effect on the firm’s Q2 bottom line remains to be seen.
Teva continues to see FY26 revenue in the range of $16.4B - $16.8B.
In June, the company submitted an NDA to the US FDA seeking approval of ecopipam, which it acquired from Emalex, for pediatric Tourette syndrome.
Seeking Alpha analyst Stephen Ayers sees the drug generating around $950M in peak annual sales, while other analysts expect it to go as high as $1B.
“I estimated a 50% peak share and a $50,000 net price per year, while the list price could be as high as $100,000 per year. I think this is a drug that will likely be "gross-to-net heavy," given that this market is saturated with dirt-cheap generics,” Ayers said.
Going into the earnings, investors are likely to watch out for the management’s comments around the drug and its impact on Teva’s P&L.
Additionally, they may also expect comments around Teva’s reignited legal battle with Eli Lilly (LLY) over an agreement that allowed the former to market a generic version of the latter's osteoporosis drug Forteo (teriparatide).
Over the last 2 years, TEVA has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time. Ahead of the earnings, Teva inched up 1.19% to $31.45.
Wall Street has projected an 83% decline in its EPS to $0.11, while revenue is expected to dip slightly by about 4% to $4.03B.
Over the last 3 months, EPS as well as revenue estimates have seen 0 upward revisions and 7 downward moves, representing a bearish setup ahead of the earnings.
Last quarter, the Israeli drugmaker beat analyst estimates but cut its full-year adjusted earnings outlook by $0.66 to the range of $1.91 - $2.11. The reduction was due to its $900M acquisition of Chicago, Illinois-based biotech firm Emalex Biosciences.
While the deal’s impact has been priced in in its full-year forecast, its effect on the firm’s Q2 bottom line remains to be seen.
Teva continues to see FY26 revenue in the range of $16.4B - $16.8B.
In June, the company submitted an NDA to the US FDA seeking approval of ecopipam, which it acquired from Emalex, for pediatric Tourette syndrome.
Seeking Alpha analyst Stephen Ayers sees the drug generating around $950M in peak annual sales, while other analysts expect it to go as high as $1B.
“I estimated a 50% peak share and a $50,000 net price per year, while the list price could be as high as $100,000 per year. I think this is a drug that will likely be "gross-to-net heavy," given that this market is saturated with dirt-cheap generics,” Ayers said.
Going into the earnings, investors are likely to watch out for the management’s comments around the drug and its impact on Teva’s P&L.
Additionally, they may also expect comments around Teva’s reignited legal battle with Eli Lilly (LLY) over an agreement that allowed the former to market a generic version of the latter's osteoporosis drug Forteo (teriparatide).
Over the last 2 years, TEVA has beaten EPS estimates 100% of the time and has beaten revenue estimates 88% of the time. Ahead of the earnings, Teva inched up 1.19% to $31.45.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。